Stay updated on Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The footer revision changes from v3.7.0 to v3.7.1. The page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T03:24:02.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error for the study record, replacing the expected study details with the site’s standard error page.
    Difference
    17%
    Check dated 2026-09-20T01:07:59.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    The page shows a new revision tag, v3.6.6, replacing the previous v3.6.5, indicating a platform update. This change does not modify the study data or visible details on the page.
    Difference
    0.1%
    Check dated 2026-08-29T19:40:22.000Z thumbnail image
  6. Check
    59 days ago
    Change Detected
    Summary
    Added the Study Protocol and Statistical Analysis Plan (PDF) to the Study Documents, along with IPD sharing information and related metadata such as source, last verified date, and publication notes.
    Difference
    45%
    Check dated 2026-08-15T19:24:43.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    The revision line in the page footer updated from v3.6.4 to v3.6.5, signaling a minor maintenance update.
    Difference
    0.1%
    Check dated 2026-08-08T16:55:14.000Z thumbnail image
  8. Check
    80 days ago
    Change Detected
    Summary
    Revision label updated from v3.6.3 to v3.6.4, signaling a version upgrade of the page. The content and study details appear unchanged.
    Difference
    0.1%
    Check dated 2026-07-25T08:22:17.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page.